← All stocks

Intellia Therapeutics, Inc.

NTLA No buying or selling
CIK 0001652130 #2130 in the set updated 21 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
$0.00
$0.00 against sales at will

By person

16 insiders · 0 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
LEONARD JOHN M
President and CEO
1,147,064
$14.91M
+19.5%
Cohen Fred E
Director
216,653
$2.82M
+338.1%
BASTA JAMES
EVP, General Counsel
156,794
$2.04M
+70.5%
Dulac Edward J III
EVP, Chief Financial Officer
148,175
$1.93M
+123.4%
CHASE WILLIAM J
Director
143,893
$1.87M
+439.1%
Schultes Birgit C
EVP, Chief Scientific Officer
137,733
$1.79M
+98.3%
Lebwohl David
EVP, Chief Medical Officer
131,192
$1.71M
+36.2%
Clark Eliana
EVP, Chief Technical Officer
93,864
$1.22M
+26.3%
Sepp-Lorenzino Laura
EVP, Chief Scientific Officer
77,388
$1.01M
−6.6%
Dube Michael P
VP, Chief Accounting Officer
66,886
$869.52K
+36.4%
Hicks Derek
EVP, Chief Business Officer
59,878
$778.41K
−9.8%
Keresty Georgia
Director
41,083
$534.08K
+72.0%
Bhanji Muna
Director
36,403
$473.24K
+84.5%
Verwiel Frank
Director
35,148
$456.92K
+95.8%
GOODMAN JESSE
Director
33,559
$436.27K
+72.5%
Goff Brian
Director
32,609
$423.92K
+111.6%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 1
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 0
History held since 5 Jan 2017